{"id":499854,"date":"2020-08-01T00:00:00","date_gmt":"2020-07-30T19:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499854"},"modified":"2020-07-30T19:56:01","modified_gmt":"2020-07-30T19:56:01","slug":"dravet-syndrome-emerging-drugs-and-key-players-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dravet-syndrome-emerging-drugs-and-key-players-delveinsight_499854.html","title":{"rendered":"Dravet Syndrome Emerging drugs and Key Players | DelveInsight"},"content":{"rendered":"
\"Dravet<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
Dravet Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Dravet Syndrome market. A detailed picture of the Dravet Syndrome pipeline landscape is provided, which includes the disease overview and Dravet Syndrome treatment guidelines.\n<\/div>\n

Dravet Syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.<\/span><\/p>\n

 <\/p>\n

Dravet Syndrome Emerging drugs <\/span><\/a><\/p>\n

Dravet Syndrome Emerging Drugs <\/strong><\/p>\n

    \n
  1. ZX008 by Zogenix<\/li>\n
  2. Soticlestat by Ovid Therapeutics<\/li>\n
  3. Ataluren by PTC Therapeutics<\/li>\n<\/ol>\n

    Dravet Syndrome Marketed Drugs<\/strong><\/p>\n

      \n
    1. Diacomit by Biocodex<\/li>\n
    2. Epidiolex by GW Pharmaceuticals<\/li>\n<\/ol>\n

       <\/p>\n

      Companies have shifted their focus on the development of second-generation therapeutics that follow the step of the most advanced cannabidiol formulation (Epidiolex) and the most advanced serotonergic drug (Fintepla). Most of these compounds would have the potential to treat other forms of epilepsy and are expected to hit Dravet Syndrome market during the forecast period of 2020–2030. <\/p>\n

       <\/p>\n

      Request for sample pages<\/a><\/p>\n

      Table of contents<\/a><\/p>\n

      1. Report Introduction<\/span><\/p>\n

      2. Dravet Syndrome <\/span><\/p>\n

      2.1. Overview<\/span><\/p>\n

      2.2. History <\/span><\/p>\n

      2.3. Dravet Syndrome Symptoms<\/span><\/p>\n

      2.4. Causes<\/span><\/p>\n

      2.5.Pathophysiology<\/span><\/p>\n

      2.6. Dravet Syndrome Diagnosis <\/span><\/p>\n

      2.6.1. Diagnostic Guidelines<\/span><\/p>\n

      3. Dravet Syndrome Current Treatment Patterns<\/span><\/p>\n

      3.1. Dravet Syndrome Treatment Guidelines<\/span><\/p>\n

      4. Dravet Syndrome – DelveInsight’s Analytical Perspective<\/span><\/p>\n

      4.1. In-depth Commercial Assessment<\/span><\/p>\n

      4.1.1. Dravet Syndrome companies collaborations, Licensing, Acquisition -Deal Value Trends<\/span><\/p>\n

      4.1.1.1. Assessment Summary<\/span><\/p>\n

      4.1.2. Dravet Syndrome Collaboration Deals<\/span><\/p>\n

      4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/span><\/p>\n

      4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/span><\/p>\n

      4.1.2.3. Dravet Syndrome Acquisition Analysis<\/span><\/p>\n

      5. Therapeutic Assessment<\/span><\/p>\n

      5.1. Clinical Assessment of Pipeline Drugs <\/span><\/p>\n

      5.1.1. Assessment by Phase of Development<\/span><\/p>\n

      5.1.2. Assessment by Product Type (Mono \/ Combination)<\/span><\/p>\n

      5.1.2.1. Assessment by Stage and Product Type<\/span><\/p>\n

      5.1.3. Assessment by Route of Administration<\/span><\/p>\n

      5.1.3.1. Assessment by Stage and Route of Administration<\/span><\/p>\n

      5.1.4. Assessment by Molecule Type<\/span><\/p>\n

      5.1.4.1. Assessment by Stage and Molecule Type<\/span><\/p>\n

      5.1.5. Assessment by MOA<\/span><\/p>\n

      5.1.5.1. Assessment by Stage and MOA<\/span><\/p>\n

      5.1.6. Assessment by Target<\/span><\/p>\n

      5.1.6.1. Assessment by Stage and Target<\/span><\/p>\n

      6. Dravet Syndrome Late Stage Products (Phase-III)<\/span><\/p>\n

      7. Dravet Syndrome Mid Stage Products (Phase-II)<\/span><\/p>\n

      8. Early Stage Products (Phase-I)<\/span><\/p>\n

      9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n

      10. Inactive Products<\/span><\/p>\n

      11. Dormant Products<\/span><\/p>\n

      12. Dravet Syndrome Discontinued Products<\/span><\/p>\n

      13. Dravet Syndrome Product Profiles<\/span><\/p>\n

      13.1. Drug Name: Company <\/span><\/p>\n

      13.1.1. Product Description<\/span><\/p>\n

      13.1.1.1. Product Overview<\/span><\/p>\n

      13.1.1.2. Mechanism of action<\/span><\/p>\n

      13.1.2. Research and Development<\/span><\/p>\n

      13.1.2.1. Clinical Studies<\/span><\/p>\n

      13.1.3. Product Development Activities<\/span><\/p>\n

      13.1.3.1. Collaboration<\/span><\/p>\n

      13.1.3.2. Agreements<\/span><\/p>\n

      13.1.3.3. Acquisition <\/span><\/p>\n

      13.1.3.4. Patent Detail<\/span><\/p>\n

      13.1.4. Tabulated Product Summary<\/span><\/p>\n

      13.1.4.1. General Description Table<\/span><\/p>\n

      14. Dravet Syndrome Key Companies<\/span><\/p>\n

      15. Dravet Syndrome Key Products<\/span><\/p>\n

      16. Dormant and Discontinued Products<\/span><\/p>\n

      16.1. Dormant Products<\/span><\/p>\n

      16.1.1. Reasons for being dormant<\/span><\/p>\n

      16.2. Discontinued Products <\/span><\/p>\n

      16.2.1. Reasons for the discontinuation<\/span><\/p>\n

      17. Dravet Syndrome Unmet Needs<\/span><\/p>\n

      18. Dravet Syndrome Future Perspectives<\/span><\/p>\n

      19. Dravet Syndrome Analyst Review  <\/span><\/p>\n

      20. Appendix<\/span><\/p>\n

      21. Report Methodology<\/span><\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight<\/a>
      Contact Person:<\/strong> Priya Maurya
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> +919650213330
      City:<\/strong> Albany
      State:<\/strong> New York
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DelveInsight Business Research LLP Dravet Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Dravet Syndrome market. A detailed picture of the Dravet Syndrome pipeline landscape is provided, which … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-499854","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=499854"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499854\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=499854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=499854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=499854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}